BeBetter Med Inc

Quick facts

Phase 3 pipeline

• BEBT-209 capsules · Diabetes
  BEBT-209 capsules are a small molecule drug that targets the SGLT2 receptor.
• BEBT-209 Placebo capluses
  This is a placebo formulation with no active pharmacological mechanism.
• Ifosfamide for Injection · Oncology
  Ifosfamide is an alkylating agent that cross-links DNA strands, preventing cancer cell replication and inducing cell death.
• Ifupinostat Hydrochloride for Injection · Oncology
  Ifupinostat is a histone deacetylase (HDAC) inhibitor that blocks HDAC enzymes to promote anti-tumor gene expression and immune activation.

Phase 2 pipeline

• BEBT-109 Capsule
• BEBT-109 Capsules
• BEBT-908 for injection

Phase 1 pipeline

• BEBT-607Tablets

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BeBetter Med Inc portfolio CI brief
• BeBetter Med Inc pipeline updates RSS